Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000634
Chunk: 10

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 10
---
 Cartesian Therapeutics, Inc. 2016 Stock Incentive Plan, or the 2016 Stock Incentive Plan, of which 964,490 options were vested as of September 30, 2024; |

| • | 334,692 shares of Common Stock issuable upon the vesting of restricted stock units outstanding as of September 30, 2024, at a weighted-average grant price of $19.88 under the 2016 Incentive Award Plan, of which no restricted stock units were vested as of September 30, 2024; |

7

TABLE OF CONTENTS

| • | 113,519 shares of Common Stock issuable upon the vesting of restricted stock units outstanding as of September 30, 2024, at a weighted-average grant price of $19.80 under the 2016 Stock Incentive Plan, of which no restricted stock units were vested as of September 30, 2024; |

| • | 974,954 shares of Common Stock issuable upon the exercise of warrants outstanding as of September 30, 2024, at a weighted average exercise price of $46.04 per share; |

| • | 3,511,101 shares of Common Stock reserved for issuance as of September 30, 2024 under the 2016 Incentive Award Plan; |

| • | 27,270 shares of Common Stock reserved for issuance as of September 30, 2024 under the 2016 Stock Incentive Plan; |

| • | 253,377 shares of Common Stock reserved for issuance as of September 30, 2024 under the Inducement Plan; and |

| • | 45,795 shares of Common Stock reserved for issuance as of September 30, 2024 pursuant to our 2016 Employee Stock Purchase Plan. |

For additional information concerning the offering, see the section titled “ Plan of Distribution.”

8

#### TABLE OF CONTENTS

### RISK FACTORS
Investing in securities issued by us involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks described under the heading “ Risk Factors ” in any of our filings with the SEC that are incorporated by reference herein.

<div align='center'>9</div>

#### TABLE OF CONTENTS

### USE OF PROCEEDS
We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered